Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 3.9% – What’s Next?

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s share price fell 3.9% during trading on Wednesday . The company traded as low as $0.9489 and last traded at $0.9511. Approximately 83,599 shares were traded during mid-day trading, a decline of 51% from the average session volume of 170,982 shares. The stock had previously closed at $0.9902.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TPST shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Monday, July 13th. Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Tempest Therapeutics Stock Performance

The stock has a 50 day moving average price of $1.28 and a 200 day moving average price of $1.90. The company has a market capitalization of $14.85 million, a P/E ratio of -0.15 and a beta of -1.73.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($2.25). As a group, sell-side analysts expect that Tempest Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Tempest Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Tempest Therapeutics by 20.8% during the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics in the 4th quarter worth approximately $33,000. Finally, Sabby Management LLC bought a new stake in shares of Tempest Therapeutics in the 4th quarter worth approximately $513,000. 22.52% of the stock is owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.